Tuesday, February 26, 2019 4:52:33 PM
As I stated, they created a joint venture with Molson Coors and there was no capital injection of money from Molson into HEXO...the shares of HEXO rose on excitement for a few day after the deal, but then they dropped back down again a few days later after the announcement due the fact that there was nothing substantive gained by HEXO. Molson Coors had approach Aphria first, and Aphria told them to take a hike because there was no investment / injection of capital being offered by HEXO.
https://www.molsoncoors.com/en/news/molson-coors-canada-and-hexo-announce-agreement-to-create-joint-venture
Whereas with Canopy and CRON, they received a sizeable injection of capital (in the billions) into their companies, this created an immediate increase in the market capitalization of these firms and translated into a sustained share price increase. Unfortunately for ACB, because they have so many shares outstanding, any kind of capital injection into the company will result in only a small increase to the price of the share (a 2 billion injection into ACB will only result in a $2 per share increase...whereas for a firm like Aphria, that would translate into an $8 a share increase).
ZenMan111, looks like you need to do a little further looking into this story ;)
https://www.molsoncoors.com/en/news/molson-coors-canada-and-hexo-announce-agreement-to-create-joint-venture
Whereas with Canopy and CRON, they received a sizeable injection of capital (in the billions) into their companies, this created an immediate increase in the market capitalization of these firms and translated into a sustained share price increase. Unfortunately for ACB, because they have so many shares outstanding, any kind of capital injection into the company will result in only a small increase to the price of the share (a 2 billion injection into ACB will only result in a $2 per share increase...whereas for a firm like Aphria, that would translate into an $8 a share increase).
ZenMan111, looks like you need to do a little further looking into this story ;)
Recent ACB News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2026 11:22:41 AM
- Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2026 Investor Conference Call and File Related Year End Information • PR Newswire (US) • 05/28/2026 11:05:00 AM
- Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2026 Investor Conference Call and File Related Year End Information • PR Newswire (Canada) • 05/28/2026 11:05:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/21/2026 09:05:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/14/2026 12:44:17 PM
- Aurora Granted Plant Breeders' Rights, Strengthening Leadership in Cannabis Science • PR Newswire (Canada) • 05/14/2026 10:54:00 AM
- Aurora Granted Plant Breeders' Rights, Strengthening Leadership in Cannabis Science • PR Newswire (US) • 05/14/2026 10:54:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/28/2026 12:15:03 PM
- Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets • PR Newswire (Canada) • 04/28/2026 10:53:00 AM
- Aurora Advances Global Medical Cannabis Portfolio with New Product Launches Across Key International Markets • PR Newswire (US) • 04/28/2026 10:53:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2026 08:18:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/15/2026 11:21:53 AM
- Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets • PR Newswire (US) • 04/15/2026 11:05:00 AM
- Aurora Cannabis Accelerates Global Medical Cannabis Leadership with Accretive Acquisition of Safari Flower Company, Expanding EU GMP Capacity to Serve Growing High Margin International Markets • PR Newswire (Canada) • 04/15/2026 11:05:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:29:57 AM
- Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year • PR Newswire (Canada) • 03/30/2026 11:03:00 AM
- Aurora Recognized for Executive Gender Diversity by the Globe & Mail for Second Consecutive Year • PR Newswire (US) • 03/30/2026 11:03:00 AM
- Aurora to Participate in the TD Cowen 46th Annual Health Care Conference • PR Newswire (US) • 02/17/2026 11:39:00 PM
- Aurora to Participate in the TD Cowen 46th Annual Health Care Conference • PR Newswire (Canada) • 02/17/2026 11:39:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/12/2026 09:26:03 PM
- Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis • PR Newswire (US) • 02/12/2026 09:05:00 PM
- Aurora to Ring the Nasdaq Closing Bell on Wednesday, February 18, 2026, Reinforcing Strategic Focus on Global Medical Cannabis • PR Newswire (Canada) • 02/12/2026 09:05:00 PM
- Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand • PR Newswire (Canada) • 02/11/2026 12:00:00 PM
- Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand • PR Newswire (US) • 02/11/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/04/2026 09:44:28 PM
